Form 4: Tango Therapeutics Director Mace Rothenberg Acquires Shares and Options

Director Mace Rothenberg acquired shares and options in Tango Therapeutics, Inc. on June 5, 2024.

Summary

• On June 5, 2024, Mace Rothenberg, a director of Tango Therapeutics, Inc., acquired 6,250 shares of common stock represented by restricted stock units (RSUs) at $0.00.
• These RSUs will vest on the earlier of June 5, 2025, or the date of the next annual meeting of stockholders, contingent upon continuous service with the Issuer.
• Rothenberg also acquired options to purchase 37,500 shares of common stock at an exercise price of $7.41.
• These options will vest in 12 equal monthly installments starting July 5, 2024, also subject to continuous service with the Issuer.
• Following these transactions, Rothenberg directly owns 11,250 shares of common stock and options for 37,500 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of insider transactions. The acquisition of shares and options by a director is generally viewed positively, but it's not a major event.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future prospects.
• The vesting schedules tied to continuous service align the director's interests with the long-term success of the company.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules suggest a commitment from the director to remain with the company for at least one year.

Industry Context

Form 4 filings are routine disclosures of insider transactions and provide transparency to the market. They are closely watched by investors for signals about management's confidence in the company.

Comparison to Industry Standards

• Stock option grants and RSU awards are common forms of executive compensation in the biotechnology industry.
• Vesting schedules tied to continued service are standard practice to incentivize long-term commitment.
• The specific terms of the grants (number of shares, exercise price, vesting schedule) would need to be compared to peer companies to assess their competitiveness.

Stakeholder Impact

• Shareholders may view the director's acquisition of shares and options as a positive sign.
• Employees may see it as an indication of management's confidence in the company's future.

Key Dates